Abstract | BACKGROUND: Case reports have suggested that treatment with high-dose etoposide can result in development of a unique secondary leukemia. PURPOSE: METHODS: We reviewed the records at Indiana University of all untreated patients entering clinical trials using etoposide at conventional doses (cumulative dose, 2000 mg/m2 or less) for germ cell cancer between 1982 and 1991. The records of all patients who received a chemotherapy regimen containing etoposide, ifosfamide, or cisplatin after failing to respond to primary chemotherapy were also reviewed. RESULTS: CONCLUSIONS: IMPLICATIONS: The reports of leukemia associated with high doses of etoposide emphasize the need for diligent follow-up of patients and make careful risk-to-benefit analysis imperative.
|
Authors | C R Nichols, E S Breeden, P J Loehrer, S D Williams, L H Einhorn |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
Vol. 85
Issue 1
Pg. 36-40
(Jan 06 1993)
ISSN: 0027-8874 [Print] United States |
PMID | 7677934
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Bleomycin
- Etoposide
- Cisplatin
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(administration & dosage)
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 4
- Cisplatin
(administration & dosage)
- Clinical Trials as Topic
- Etoposide
(administration & dosage, adverse effects)
- Humans
- Leukemia
(chemically induced, genetics)
- Leukemia, Monocytic, Acute
(chemically induced)
- Leukemia, Myeloid, Acute
(chemically induced)
- Male
- Neoplasms, Germ Cell and Embryonal
(drug therapy)
- Neoplasms, Second Primary
(chemically induced)
- Retrospective Studies
- Salvage Therapy
- Testicular Neoplasms
(drug therapy)
- Translocation, Genetic
|